亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)

医学 卵巢癌 危险系数 紫杉醇 内科学 无进展生存期 安慰剂 临床终点 胃肠病学 化疗 随机对照试验 外科 癌症 肿瘤科 泌尿科 置信区间 病理 替代医学
作者
Rebecca C. Arend,Bradley J. Monk,Ronnie Shapira‐Frommer,Ashley Haggerty,Edwin Alvarez,Amit Agarwal,Angeles Alvarez Secord,Carolyn Y. Muller,Antonio Casado Herráez,Thomas J Herzog,Krishnansu S. Tewari,Joshua G. Cohen,Marilyn Huang,Adelya Yachnin,Laura L. Holeman,Jonathan A. Ledermann,Tamar Rachmilewitz Minei,Marc Buyse,Shifra Fain Shmueli,Michal Lavi,Dror Harats,Richard T. Penson,Bhavana Pothuri,Jean-Marie Stéphan,Michael J. Callahan,William E. Bradley,Purificación Estévez,Mayu Yunokawa,Setsuko K. Chambers,Laura L. Holman,Lisa M. Landrum,John Seidel,Samuel S. Lentz,Lisa Barroilhet,Georgia A. McCann,Ora Rosengarten,Daliah Tsoref,Joseph A. Lucci,Joyce N. Barlin,Evelyn Fleming,Linda Van Le,Veena John,Cristina Churucca,Paweł Blecharz,Shani Breuer,Thomas Reid,Mary Cunningham,Andrea Jewell,Frederick R. Ueland,Michael Teneriello,Thomas Woliver,Iwona Podzielinski,Dana M. Roque,Thomas C. Krivak,Heidi Godoy,Marta Gil,Yolanda García,Rodryg Ramlau,Masashi Takano,Shin Nishio,Maria T. Grosse-Perdekamp,Nicholas Taylor,Sara Rodríguez Pérez,Kazuki Sudo,Takashi Matsumoto,Hideki Tokunaga,Stefanie Morris,James F. Barter,Merry Jennifer Markham,Amy Brown,Julian C. Schink,Maria C. Bell,Raúl Márquez,Cristina Caballero,Tomasz Kubiatowski,Akira Kikuchi,Kenichi Harano,Masahiro Kagabu,Irina Dimitrova,Jeffrey Elder,Tariq Mahmood,Cheung Wong,Nana Tchabo,Christina Chu,Mark H. Einstein,John Farley,Charles Anderson,Ignacio Romero Noguera,Hidemichi Watari,S. Suzuki,Tsuyoshi Saito
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:42 (2): 170-179
标识
DOI:10.1200/jco.22.02915
摘要

PURPOSE To evaluate the addition of ofranergene obadenovec (ofra-vec, VB-111), a novel gene-based anticancer targeted therapy, to once a week paclitaxel in patients with recurrent platinum-resistant ovarian cancer (PROC). METHODS This placebo-controlled, double-blind, phase III trial (ClinicalTrials.gov identifier: NCT03398655 ) randomly assigned patients with PROC 1:1 to receive intravenous ofra-vec every 8 weeks with once a week IV paclitaxel or placebo with paclitaxel until disease progression. The dual primary end points were overall survival (OS) and progression-free survival (PFS) as assessed by Blinded Independent Central Review. RESULTS Between December 2017 and March 2022, 409 patients were randomly assigned. The median PFS was 5.29 months in the ofra-vec arm and 5.36 months in the control arm, hazard ratio (HR) 1.03 (CI, 0.83 to 1.29; P = .7823). The median OS with ofra-vec was 13.37 months versus 13.14 months, HR 0.97 (CI, 0.75 to 1.27; P = .8440). Objective response rates (ORRs) per RECIST 1.1 were similar in both arms: 28.9% with ofra-vec versus 29.6% with control. In both treatment arms, response to CA-125 was a substantial prognostic factor for both PFS and OS. In the ofra-vec arm, the HR in CA-125 responders compared with that in nonresponders for PFS was 0.2428 (CI, 0.1642 to 0.3588), and for OS, the HR was 0.3343 (CI, 0.2134 to 0.5238). Safety profile was characterized by common transient flu–like symptoms such as fever and chills. CONCLUSION The addition of ofra-vec to paclitaxel did not improve PFS or OS. The PFS and ORR in the control arm exceeded the results that were anticipated on the basis of the AURELIA chemotherapy control arm. CA-125 response was a substantial prognostic biomarker for PFS and OS in patients with PROC treated with paclitaxel.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lixuebin完成签到 ,获得积分10
19秒前
七七发布了新的文献求助10
42秒前
大个应助科研通管家采纳,获得10
48秒前
白云朵儿发布了新的文献求助10
54秒前
57秒前
Orange应助七七采纳,获得10
1分钟前
酷波er应助guan采纳,获得10
1分钟前
CodeCraft应助wanwan47采纳,获得10
1分钟前
wanwan47完成签到,获得积分10
2分钟前
ruba发布了新的文献求助10
2分钟前
2分钟前
老弍发布了新的文献求助10
2分钟前
ruba关注了科研通微信公众号
2分钟前
3分钟前
3分钟前
白云朵儿发布了新的文献求助10
3分钟前
3分钟前
guan发布了新的文献求助10
3分钟前
3分钟前
老弍发布了新的文献求助10
3分钟前
guan完成签到,获得积分20
4分钟前
4分钟前
连安阳发布了新的文献求助10
4分钟前
Ann完成签到,获得积分10
4分钟前
4分钟前
白云朵儿发布了新的文献求助10
5分钟前
wangfaqing942完成签到 ,获得积分10
6分钟前
FashionBoy应助zhao123123采纳,获得30
6分钟前
7分钟前
zhao123123发布了新的文献求助30
7分钟前
明理的夜蓉完成签到 ,获得积分10
7分钟前
7分钟前
zhao123123完成签到,获得积分10
7分钟前
白云朵儿发布了新的文献求助10
7分钟前
8分钟前
8分钟前
YUNUN发布了新的文献求助10
8分钟前
9分钟前
orixero应助海燕采纳,获得30
9分钟前
9分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
行動データの計算論モデリング 強化学習モデルを例として 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2545602
求助须知:如何正确求助?哪些是违规求助? 2175642
关于积分的说明 5600185
捐赠科研通 1896371
什么是DOI,文献DOI怎么找? 946248
版权声明 565371
科研通“疑难数据库(出版商)”最低求助积分说明 503557